Inari Medical, Inc. (NASDAQ:NARI – Get Free Report) CFO Mitch C. Hill sold 6,000 shares of the company’s stock in a transaction that occurred on Friday, April 12th. The shares were sold at an average price of $40.96, for a total value of $245,760.00. Following the completion of the transaction, the chief financial officer now owns 181,294 shares in the company, valued at approximately $7,425,802.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Inari Medical Stock Performance
Inari Medical stock opened at $38.59 on Friday. The stock has a market cap of $2.24 billion, a P/E ratio of -1,286.33 and a beta of 0.84. Inari Medical, Inc. has a fifty-two week low of $37.92 and a fifty-two week high of $71.85. The firm’s fifty day moving average price is $46.89 and its 200-day moving average price is $55.32.
Inari Medical (NASDAQ:NARI – Get Free Report) last released its quarterly earnings results on Wednesday, February 28th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.09). The firm had revenue of $132.10 million during the quarter, compared to the consensus estimate of $131.82 million. Inari Medical had a positive return on equity of 1.23% and a negative net margin of 0.33%. The company’s revenue for the quarter was up 22.5% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.11) EPS. Sell-side analysts predict that Inari Medical, Inc. will post -0.39 earnings per share for the current year.
Analyst Upgrades and Downgrades
Get Our Latest Stock Report on NARI
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. Parkside Financial Bank & Trust bought a new position in shares of Inari Medical in the first quarter worth $25,000. Quarry LP bought a new position in Inari Medical in the second quarter valued at $27,000. Fifth Third Bancorp increased its stake in Inari Medical by 54.3% in the third quarter. Fifth Third Bancorp now owns 486 shares of the company’s stock valued at $32,000 after acquiring an additional 171 shares during the last quarter. Point72 Middle East FZE bought a new position in Inari Medical in the fourth quarter valued at $55,000. Finally, FMR LLC increased its stake in Inari Medical by 42.6% in the second quarter. FMR LLC now owns 824 shares of the company’s stock valued at $56,000 after acquiring an additional 246 shares during the last quarter. Institutional investors own 90.98% of the company’s stock.
Inari Medical Company Profile
Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.
Further Reading
- Five stocks we like better than Inari Medical
- How Investors Can Find the Best Cheap Dividend Stocks
- Comprehensive Analysis of PayPal Stock
- Are Penny Stocks a Good Fit for Your Portfolio?
- Intuitive Surgical Stock Can Trend Much Higher This YearÂ
- 3 Warren Buffett Stocks to Buy Now
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for Inari Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inari Medical and related companies with MarketBeat.com's FREE daily email newsletter.